©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2015; 7(10): 241-249
Published online Oct 15, 2015. doi: 10.4251/wjgo.v7.i10.241
Published online Oct 15, 2015. doi: 10.4251/wjgo.v7.i10.241
Management of borderline resectable pancreatic cancer
Amit Mahipal, Richard Kim, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
Jessica Frakes, Sarah Hoffe, Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
Conflict-of-interest statement: None.
Correspondence to: Richard Kim, MD, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive FOB-2, Tampa, FL 33612, United States. richard.kim@moffitt.org
Telephone: +1-813-7451277 Fax: +1-813-7457229
Received: April 15, 2015
Peer-review started: April 16, 2015
First decision: July 1, 2015
Revised: July 7, 2015
Accepted: August 10, 2015
Published online: October 15, 2015
Processing time: 187 Days and 4.2 Hours
Peer-review started: April 16, 2015
First decision: July 1, 2015
Revised: July 7, 2015
Accepted: August 10, 2015
Published online: October 15, 2015
Processing time: 187 Days and 4.2 Hours
Core Tip
Core tip: The diagnosis and treatment of borderline resectable pancreatic cancer (BRPC) remains unclear. The definition of BRPC is not uniform and generally refers to regional blood vessel involvement by the tumor. Recent attempts have been made to standardize the definition of BRPC. Neoadjuvant therapy is recommended in the hopes of obtaining negative surgical margins and consists of chemotherapy and radiation therapy. Data for therapeutic approaches is primarily derived from single institution retrospective series. In this article, we review the definition, imaging modalities for diagnosis and treatment of patients with BRPC.